Last reviewed · How we verify

Acute Lymphoblastic Leukemia (ALL) — Treatment Landscape & Competitive Intelligence

Acute Lymphoblastic Leukemia (ALL) (Haematology / Oncology) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Haematology / Oncology 2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute Lymphoblastic Leukemia (ALL), deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Asparlas CALASPARGASE PEGOL Servier Pharma Llc Asparagine-specific Enzyme [EPC] 2018-01-01
Doxorubicin Hydrochloride Doxorubicin Hydrochloride Pfizer Inc. Anthracycline topoisomerase inhibitor DNA topoisomerase II, nucleotide bases

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Acute Lymphoblastic Leukemia (ALL)
  2. Servier Pharma Llc · 1 drug in Acute Lymphoblastic Leukemia (ALL)

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute Lymphoblastic Leukemia (ALL):

Cite this brief

Drug Landscape (2026). Acute Lymphoblastic Leukemia (ALL) — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-lymphoblastic-leukemia. Accessed 2026-05-15.

Related